GOOD DOCTOR ·
Company was founded
Manufacturing facilities
Times of successful performance
Independent Intellectual Property Rights
Xi’an Good Doctor Medical Science Technology Co., Ltd.
Manufacturer of the GDHIPEC System
Innovation in HIPEC & HITHOC Technology
Your Reliable Partner in Hyperthermic Perfusion
GDPR-2100S
Innovation in HIPEC Technology The Most Advanced Hyperthermic Perfusion System in China
The Most Advanced Hyperthermic Perfusion System in China
GDPR-2100S from the GDHIPEC, the most reliable and dedicated system (equipment and consumable accessories) for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Hyperthermic Intrathoracic Chemotherapy (HITHOC) in China.
Learn moreMinimally Invasive Treatment
Precise Temperature Control
Outstanding Clinical Performance
Innovative “One-way” Lavage Technology
Applicable for Both Surgical and Medical Oncology
GDPR-2100T
Innovation in HIPEC Technology The Most Advanced Hyperthermic Perfusion System in China
The Most Advanced Hyperthermic Perfusion System in China
GDPR-2100T from the GDHIPEC, the most reliable and dedicated system (equipment and consumable accessories) for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Hyperthermic Intrathoracic Chemotherapy (HITHOC) in China.
Learn moreGDHIPEC ·
GDHIPEC
Broadly Applicable to Both Surgical and Medical Oncology Treatment Strategies
Multiple cavities・Minimal damage・Control metastasis・Treat effusion
Academic publications & professional resources
Holds more than 20 independent intellectual property rights
Keep abreast of market dynamics, focus on Good Doctor information
BLOG
The National Cancer Center has just released: 2024 National Cancer Report
Recently, with the approval of the National Health Commission, the National Cancer Center released the 2022 burden of malignant tumors in China based on the latest data from tumor registration and follow-up monitoring on JNCC. The results released this time are jointly calculated by the National Cancer Center and the International Agency for Research on Cancer (IARC), consistent with the Chinese data published by IARC in GLOBOCAN 2022 and released simultaneously.